HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fu-Mei Huang Selected Research

Cetrimonium (CTAB)

12/2021Cetyltrimethylammonium Bromide Disrupts Mesenchymal Characteristics of Human Tongue Squamous Cell Carcinoma SCC4 Cells Through Modulating Canonical TGF-β/Smad/miR-181b/TIMP3 Signaling Pathway.
8/2021Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
9/2020Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling.
8/2020Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells Via Inactivation of c-Met/PI3K/Akt/mTOR Pathway.
7/2019Cetrimonium Bromide Inhibits Cell Migration and Invasion of Human Hepatic SK-HEP-1 Cells Through Modulating the Canonical and Non-canonical TGF-β Signaling Pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Fu-Mei Huang Research Topics

Disease

15Inflammation (Inflammations)
03/2023 - 03/2003
4Neoplasm Metastasis (Metastasis)
08/2021 - 08/2019
4Periodontal Diseases (Periodontal Disease)
10/2006 - 08/2002
3Gingival Overgrowth
08/2016 - 10/2013
2Neoplasms (Cancer)
10/2022 - 12/2018
2Chromosome Aberrations (Chromosome Abnormalities)
01/2008 - 07/2007
2Osteosarcoma (Osteogenic Sarcoma)
10/2006 - 06/2004
2Periodontitis
10/2006 - 06/2004
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2021
1Squamous Cell Carcinoma of Head and Neck
08/2021
1Multiple Sclerosis
12/2020
1Thymoma (Thymic Carcinoma)
09/2020
1Liver Neoplasms (Liver Cancer)
09/2020
1Adenocarcinoma
07/2019
1Communicable Diseases (Infectious Diseases)
04/2019
1Asthma (Bronchial Asthma)
12/2018
1Fibrosis (Cirrhosis)
06/2016
1Hypoxia (Hypoxemia)
01/2015
1Wounds and Injuries (Trauma)
04/2014
1Oral Submucous Fibrosis
09/2013
1Bone Resorption
03/2009
1Radicular Cyst
03/2004
1Bacterial Infections (Bacterial Infection)
05/2003
1Disease Progression
03/2003
1Infections
02/2003

Drug/Important Bio-Agent (IBA)

6EnzymesIBA
10/2005 - 03/2003
6ProstaglandinsIBA
10/2005 - 03/2003
5Cetrimonium (CTAB)IBA
12/2021 - 07/2019
5Cyclooxygenase 2 (Cyclooxygenase-2)IBA
10/2005 - 05/2003
4Messenger RNA (mRNA)IBA
09/2005 - 10/2004
3Proteins (Proteins, Gene)FDA Link
09/2020 - 01/2015
3Cyclosporine (Ciclosporin)FDA LinkGeneric
08/2016 - 10/2013
3Formaldehyde (Formol)FDA Link
11/2007 - 03/2004
2Rutin (Rutoside)IBA
03/2023 - 10/2022
2VimentinIBA
09/2020 - 08/2020
2Cadherins (E-Cadherin)IBA
09/2020 - 08/2020
2Phosphatidylinositols (Phosphatidylinositol)IBA
09/2020 - 08/2020
2Endocrine DisruptorsIBA
04/2019 - 12/2018
2Plasminogen Activator Inhibitor 1IBA
01/2015 - 03/2004
2Plasminogen Activators (Plasminogen Activator)IBA
01/2015 - 03/2004
2Plasminogen InactivatorsIBA
01/2015 - 03/2004
2GelatinasesIBA
03/2008 - 06/2004
2Reducing AgentsIBA
01/2008 - 07/2007
2dimethyl-4-toluidineIBA
01/2008 - 07/2007
22- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA
10/2006 - 06/2004
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
10/2006 - 06/2004
2Interleukin-1alpha (Interleukin 1 alpha)IBA
10/2006 - 06/2004
2U 0126 (UO 126)IBA
10/2006 - 06/2004
2Tissue Plasminogen Activator (Alteplase)FDA Link
10/2006 - 03/2004
2SB 203580IBA
10/2006 - 06/2004
2Matrix Metalloproteinases (MMPs)IBA
12/2005 - 06/2004
2Dentin-Bonding AgentsIBA
10/2005 - 08/2004
2Epoxy ResinsFDA Link
09/2005 - 05/2005
2CytokinesIBA
10/2004 - 03/2003
1Ammonium CompoundsIBA
08/2021
1Surface-Active Agents (Surfactants)IBA
08/2021
1Dental AmalgamIBA
12/2020
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
09/2020
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
09/2020
1Monomeric GTP-Binding ProteinsIBA
09/2020
1Tissue Inhibitor of MetalloproteinasesIBA
09/2020
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
09/2020
1Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
09/2020
1Basic Helix-Loop-Helix Transcription FactorsIBA
09/2020
1Ribosomal Protein S6 Kinases (S6 Kinase)IBA
08/2020
1TOR Serine-Threonine KinasesIBA
08/2020
170-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA
08/2020
1Insulin-Like PeptidesIBA
08/2019
1Immunosuppressive Agents (Immunosuppressants)IBA
08/2016
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2016
1Local Anti-Infective Agents (Antiseptics)IBA
04/2014
1ChlorhexidineIBA
04/2014
1Thrombin Receptors (Thrombin Receptor)IBA
09/2013
1Peptide Hydrolases (Proteases)FDA Link
09/2013
1Composite ResinsIBA
01/2013
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2009
1RANK LigandIBA
03/2009
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
10/2006
1InterleukinsIBA
09/2005
1Interleukin-6 (Interleukin 6)IBA
09/2005
1EugenolIBA
09/2005
1Interleukin-8 (Interleukin 8)IBA
09/2005
1Zinc OxideFDA Link
09/2005
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2004
1GelatinIBA
06/2004
1AntigensIBA
03/2004
1ParaffinIBA
03/2004
1Hematoxylin (Haematoxylon)IBA
03/2004
1Eosine Yellowish-(YS) (Eosin)IBA
03/2004
1FibrinolysinFDA Link
05/2003
1PlasminogenIBA
05/2003
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
03/2003
1AgarIBA
02/2003
1Superoxide DismutaseIBA
08/2002
1Buthionine SulfoximineIBA
08/2002
1AntioxidantsIBA
08/2002
1CatalaseIBA
08/2002

Therapy/Procedure

4Therapeutics
10/2006 - 08/2002
1Oral Hygiene (Dental Hygiene)
04/2014
1Chemoprevention
08/2002